Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders.
$41.22
+$1.12 (+2.79%)
EOD Oct 16, 2026
17.21% operating margin is respectable but not wide. ROIC at 11.91%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 5.2% YoY. Margins deteriorated 9.8pp alongside, both lines moving the wrong way.
At 108x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 22.41% to 11.91%, capital efficiency is deteriorating.
108.5x earnings, 31.2x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.67B
▼ -5.2% YoY
Net Income (TTM)
$66M
▼ -34.2% YoY
Op. Margin
7.03%
▼ -9.8pp YoY
ROIC
3.31%
▼ -10.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$222M
▲ +18.4% YoY
Op. Cash Flow (TTM)
$251M
▲ +18.6% YoY
Net Debt
$916M
Cash & Equiv.
$657M
5Y CAGR: +7.3%
5Y CAGR: +63.9%
Continue Research
SourceComputed from the 10-Q filed 23 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 29 Jul 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Alkermes (ALKS) overvalued?
At a P/E of 108.5 and a price-to-free-cash-flow of 31.2, Alkermes (ALKS) trades below a two-stage DCF intrinsic value of about $59.22 per share, so at $41.22 the stock looks undervalued (43.7% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Alkermes scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Alkermes's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $59.22 per share for ALKS, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $44.41. At today's $41.22, that puts the stock about 43.7% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Alkermes a high-quality business?+
Alkermes scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 7.0% operating margin and a 3.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Alkermes a good stock to buy right now?+
That depends on valuation and quality together, not either alone. ALKS currently trades below its estimated intrinsic value and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.